Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+


  Malignant Melanoma

  Free Subscription


08.04.2019

1 Ann Surg Oncol
2 Clin Cancer Res
1 Cutis
1 Int J Cancer
2 J Am Acad Dermatol
2 J Clin Oncol
1 J Immunol
1 J Immunother
2 Lancet Oncol
3 Melanoma Res
2 N Engl J Med
1 Oncogene
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. MIURA JT, Dossett LA, Thapa R, Kim Y, et al
    Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes.
    Ann Surg Oncol. 2019 Apr 4. pii: 10.1245/s10434-019-07333.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  2. WU RY, Kong PF, Xia L, Huang Y, et al
    Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.
    Clin Cancer Res. 2019 Apr 2. pii: 1078-0432.CCR-18-2840.
    PubMed     Text format     Abstract available

  3. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Text format     Abstract available


    Cutis

  4. BASHLINE BR, Bedocs PM
    Vemurafenib-induced plantar hyperkeratosis.
    Cutis. 2018;102:E19-E21.
    PubMed     Text format    


    Int J Cancer

  5. ANTONIAZZI CTD, Nassini R, Rigo FK, Milioli AM, et al
    Transient receptor potential ankyrin 1 (TRPA1) plays a critical role in a mouse model of cancer pain.
    Int J Cancer. 2019;144:355-365.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  6. FARIES MB, Cochran AJ, Thompson JF
    Re: "Time to Reconsider the Role of Sentinel Lymph Node Biopsy in Melanoma".
    J Am Acad Dermatol. 2019 Mar 27. pii: S0190-9622(19)30508.
    PubMed     Text format    

  7. DEWANE ME, Kelsey A, Oliviero M, Rabinovitz H, et al
    Melanoma on Chronically Sun Damaged Skin: Lentigo Maligna and Desmoplastic Melanoma.
    J Am Acad Dermatol. 2019 Mar 28. pii: S0190-9622(19)30510.
    PubMed     Text format     Abstract available


    J Clin Oncol

  8. HESS KR
    Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAF(V600)-Mutant Stage III Melanoma Seems to be Short-Lived.
    J Clin Oncol. 2019 Apr 2:JCO1801768. doi: 10.1200/JCO.18.01768.
    PubMed     Text format    

  9. HINDIE E
    What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?
    J Clin Oncol. 2019 Apr 2:JCO1802075. doi: 10.1200/JCO.18.02075.
    PubMed     Text format    


    J Immunol

  10. GILFILLAN CB, Kuhn S, Baey C, Hyde EJ, et al
    Clec9A(+) Dendritic Cells Are Not Essential for Antitumor CD8(+) T Cell Responses Induced by Poly I:C Immunotherapy.
    J Immunol. 2018;200:2978-2986.
    PubMed     Text format     Abstract available


    J Immunother

  11. AFZAL MZ, Shirai K
    Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    J Immunother. 2019 Mar 29. doi: 10.1097/CJI.0000000000000265.
    PubMed     Text format     Abstract available


    Lancet Oncol

  12. SMITHERS BM
    Conclusions from quality of life studies in patients with resected high-risk melanoma: one part of the full story.
    Lancet Oncol. 2019 Mar 27. pii: S1470-2045(19)30176.
    PubMed     Text format    

  13. SCHADENDORF D, Hauschild A, Santinami M, Atkinson V, et al
    Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Mar 27. pii: S1470-2045(18)30940.
    PubMed     Text format     Abstract available


    Melanoma Res

  14. MARIC H, Supic G, Kandolf-Sekulovic L, Maric V, et al
    DNMT1 and DNMT3B genetic polymorphisms affect the clinical course and outcome of melanoma patients.
    Melanoma Res. 2019 Apr 3. doi: 10.1097/CMR.0000000000000612.
    PubMed     Text format     Abstract available

  15. NEELAM S, Mellon J, Wilkerson A, Niederkorn JY, et al
    Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.
    Melanoma Res. 2019 Mar 29. doi: 10.1097/CMR.0000000000000614.
    PubMed     Text format     Abstract available

  16. MIKKELSEN LH, Andersen MK, Andreasen S, Larsen AC, et al
    Global microRNA profiling of metastatic conjunctival melanoma.
    Melanoma Res. 2019 Mar 29. doi: 10.1097/CMR.0000000000000606.
    PubMed     Text format     Abstract available


    N Engl J Med

  17. LONG GV, Gasal E, Hauschild A
    Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply.
    N Engl J Med. 2019;380:1376-1377.
    PubMed     Text format    

  18. EGGERMONT A, Suciu S, Kicinski M
    Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma.
    N Engl J Med. 2019;380:1374-1376.
    PubMed     Text format    


    Oncogene

  19. GHOSHAL A, Rodrigues LC, Gowda CP, Elcheva IA, et al
    Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis.
    Oncogene. 2019 Apr 1. pii: 10.1038/s41388-019-0797.
    PubMed     Text format     Abstract available


    PLoS One

  20. CONSOLI F, Manganoni AM, Grisanti S, Petrelli F, et al
    Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
    PLoS One. 2019;14:e0214884.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: